Year-end report 2020

Q4, October - December ·Net sales amounted to MSEK 721.2 (649.3). This corresponds to an increase of 11% for the period. ·The organic growth* during the fourth quarter was +1%. The currency impact in the quarter was -1% while the acquisitions of the product portfolios Proct[® ]from Leo Pharma and Pevaryl[® ]from Johnson & Johnson generated growth of 11%. ·EBIT (Operating Profit) amounted to MSEK -19.4 (8.2). ·Adjusted EBITDA* amounted to MSEK 164.8 (151.4) corresponding to growth of 9% excluding non-recurring items related to acquired product portfolios totalling